In a large patient group and biotech collaboration, Joining Jack is delighted to announce their partnership with Solid Ventures, The Duchenne Children's Trust and the Duchenne Research Fund for the launch of Solid GT, a Solid Ventures company focused on gene therapy for patients with Duchenne muscular dystrophy. Gene therapy has the potential to change the course of this disease for ALL patients with DMD.
The three UK foundations said: “The Duchenne Research Fund, The Duchenne Children’s Trust and Joining Jack are thrilled to partner with Solid Ventures on the launch of Solid GT. We are proud to play a role in such an ambitious and driven project, and one that involves leading global experts on DMD, gene therapy and clinical trial design and execution. Solid GT’s programme is extremely exciting and it fits perfectly with our agenda, to partner and enhance groundbreaking drug development efforts and clinical trials, and to bring treatments to the whole DMD community as quickly and safely as possible”
For more details please visit: http://www.solid-ventures.com/